Episode 252: Today, Ann explains the Treasury’s decision to double its debt buybacks — and what could be driving the move. Then, we spin through market headlines, including earnings from Estée Lauder and Target, why Moderna stock is surging and robotics maker Unitree’s blockbuster IPO. Finally, we take a listener&#x27;s question and dive into CRISPR Therapeutics to unpack why the biotech company behind the world’s first approved gene-editing therapy still isn’t profitable. Visit Schwab.com/FinancialDecoder www.brewmarkets.com Subscribe to the Brew Markets newsletter: https://www.morningbrew.com/brew-mark... Follow Brew Markets on social: Instagram: instagram.com/brewmarkets TikTok: tiktok.com/@brewmarkets X: x.com/brewmarkets Follow Ann Berry on social: Instagram: instagram.com/annberry_nyc X: x.com/AnnBerry_NYC Listen to Brew Markets Here: swap.fm/l/9Qk4z73Z2nEwFiCB4qee Watch Brew Markets Here:⁠ https://www.youtube.com/@BrewMarkets The content shared on this podcast is for informational and entertainment purposes only and should not be considered financial, legal, or investment advice. Brew Markets, Morning Brew and their hosts are not licensed financial advisors. Listeners should conduct their own research and consult with qualified professionals before making any financial decisions or investments. The views expressed are those of the hosts and guests and do not necessarily reflect the views of Morning Brew or its affiliates. This podcast may include paid endorsements or sponsorships Learn more about your ad choices. Visit megaphone.fm/adchoices

Why the Treasury is Buying U.S. Debt & Commercializing Gene Editing

Brew Markets

Target and Estee Lauder, two major turnaround stories getting a boost today. We break down what's working. CRISPR Therapeutics, developer of the world's first approved gene editing therapy. Sales are growing, so why is the company still losing money? We answer one listener's question. And interest rates, as the Treasury buys back government bonds in its latest move, we survey what's going on in Washington. For Wednesday, August 19th, it's Brew Markets Daily and I'm Ann Berry.

More market details to come, but first, Treasury intervention. We've talked about it on the show before when it's caught our attention. So don't let your eyes glaze over yet. I know you want to, but do stick with us because these interventions are usually signs of bigger, interesting forces at work. Well, most recently, we talked about Treasury intervention when it comes to currencies. Torsten Slock, Chief Economist at Apollo Global Management, joined us exactly two weeks ago to

describe how the United States Treasury had just bought Japanese yen at scale. That was in a highly unusual attempt to prevent the Japanese government from selling U.S. bonds, which in turn could push U.S. interest rates up. Something which the White House does not want to see happening, especially in the U.S. run up right now to midterm elections. Well, today, another striking move came to light from the U.S. Treasury,

announcing that starting September 9th, it will double the maximum size of its buybacks of 10 to 30 year government bonds from $2 billion right now to at least $4 billion. And here's the unusual part. Washington is doing this while simultaneously borrowing enormous amounts of new money. So the Treasury is effectively selling new bonds while buying back older ones.

Why the Treasury is Buying U.S. Debt & Commercializing Gene Editing

Read the full transcript

The candid version is on a podcast,
not the earnings call.

Why the Treasury is Buying U.S. Debt & Commercializing Gene Editing

Read the full transcript

The candid version is on a podcast, not the earnings call.

The candid version is on a podcast,
not the earnings call.